What UlcerGard Treats: Main Uses and Benefits

UlcerGard is used in situations involving certain distressing symptoms, applied across the therapeutic domain of equine gastric ulcer prevention. The medication is commonly used in conditions where patients experience a heightened risk of lesion development, which is the primary condition it is designed to address. The primary application is the prevention of gastric ulcers.

The medication may be considered relevant in contexts marked by increased discomfort or tension, applied in clinical settings that involve acute or unstable symptom patterns. It is commonly used when short-term symptomatic assistance is needed during phases of high physiological stress from intensive training, competition, traveling, or prolonged stall confinement. This is applied in addressing symptom clusters that may become intense or disruptive.

The medication is considered relevant for managing symptoms associated with a heightened risk of ulcer formation, including intermittent colic, noticeable behavior changes, and decreased appetite. The medication generally contributes to improved comfort during periods of heightened symptoms. This supportive benefit assists with maintaining functional stability by managing secondary symptomatic manifestations, which may help patients cope more steadily with symptom fluctuations.

---

Quick Fact: Supportive Management of Gastric Symptom Risk

• Supportive Benefit: Provides assistance that helps ease the overall symptom burden associated with high-stress scenarios.

  ---

Regulatory References

1. FDA Freedom of Information Summary for UlcerGard

Eligibility Map: Who can and cannot use UlcerGard — official regulatory information

---

Eligibility scope

Populations for whom use is allowed (as stated in label): Equine (Horses), including breeding stallions. Populations for whom use is not recommended (if applicable): Pregnant mares, lactating mares, and foals/weanlings. Populations for whom use is contraindicated: Humans, horses intended for human consumption, and animals with known hypersensitivity to the active ingredient.

Age-related eligibility rules: Use is established only in horses weighing at least 600 lbs (272 kg). Effectiveness for prevention has not been evaluated in foals and weanlings.

Condition-specific eligibility rules: Horses with liver disease or decreased liver function require caution. The product is intended for otherwise healthy horses.

Pregnancy and lactation eligibility status (if explicitly documented): Safety in pregnant mares and lactating mares has not been determined, resulting in a status of not recommended.

Eligibility-related restrictions: The primary restriction is a minimum body weight threshold of 600 lbs.

---

Eligibility classifications (high-level)

Eligibility severity classification (as defined in official documents): Contraindicated (e.g., humans), Not Recommended (e.g., pregnant mares), and Allowed (e.g., breeding stallions). Regulatory basis (EMA / FDA / etc.): Primarily based on FDA Prescribing Information (NADA 141-227) and supporting regulatory data. Eligibility-context constraints (as defined in official documents): Species-specific, weight-dependent, food safety-dependent, and reproductive status-dependent.

---

Resulting eligibility structure

Official eligibility statements:

• The medicine is contraindicated for humans and horses intended for human consumption.
• Use is not recommended for pregnant or lactating mares due to unestablished safety data.
• Eligibility requires a minimum body weight of 600 lbs.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use the medicine by establishing absolute prohibitions based on species, food safety, and hypersensitivity, while applying restrictions to pregnant and lactating groups, and enforcing a minimum weight requirement for use.

Interactions with other medicines and products

The official regulatory profile for UlcerGard (Omeprazole Oral Paste), a veterinary medicine, is largely characterized by the absence of formally documented drug-drug interactions. The specific regulatory label for this product, as reviewed by the United States Food and Drug Administration (FDA), does not include a dedicated section listing pharmacokinetic, metabolic, or transporter-based interactions with named medicinal products.

---

Interaction Scope and Classification

The single established interaction principle is strictly pharmacodynamic, derived from the drug's core approved action. As a Proton Pump Inhibitor, UlcerGard provides sustained gastric acid suppression, which results in a significant increase in gastric pH. This chemical alteration can potentially change the absorption of other medicines co-administered that require an acidic environment for adequate dissolution and bioavailability. This interaction is a principle of the drug class rather than a specific documented drug-drug warning.

---

Interaction-Related Restrictions

The official prescribing information for this veterinary product does not classify any combination of medicinal products as formally contraindicated due to an interaction risk. Furthermore, the regulatory label does not mandate specific timing separation rules for co-administration with any other substances, nor does it list specific interactions with food, alcohol, or herbal products. The label is also silent on population-specific interaction cautions, such as those related to hepatic function. The resulting interaction structure is defined by the absence of formally stated constraints in the official regulatory documents.

Targeting the Acid Production Mechanism

This drug's action is defined by its ability to act as an irreversible inhibitor of the H^+/ K^+-ATPase enzyme, commonly known as the proton pump, which is found in the stomach's parietal cells. The active ingredient is converted into its inhibitory form in the acidic microenvironment of the parietal cell, ensuring the action is highly localized. This specific interaction is the final step in the gastric acid secretion pathway and is the core mechanism that determines the drug's effect profile.

The Cascade of Systemic Acid Suppression

Once the drug's active form binds covalently to the proton pump, it permanently blocks the release of hydrogen ions into the stomach. This blockage initiates a cascade leading to a marked reduction in the stomach's overall acidity. This resulting physiological state of low gastric acid alters the gastric environment to one that is compatible with the restoration of mucosal integrity within the upper digestive tract.

How UlcerGard is Used

UlcerGard (Omeprazole Oral Paste) is administered according to a specific, standardized protocol for the prevention of gastric ulcers in horses. Use is limited to the oral route.

---

Dosing and Administration Protocol

The product is dispensed as a paste from an adjustable-dose syringe and must be administered once daily. The minimum effective dose for prevention is 1 mg/kg (0.45 mg/lb) of the horse’s body weight.

Horse Weight Range	Daily Dose Recommendation (Once Daily)
600 lbs to 1200 lbs	1 dose (1/4 syringe)
Over 1200 lbs	2 doses (1/2 syringe)

Administration must occur when the horse’s mouth is free of feed to maximize absorption. The paste should be deposited entirely on the back of the tongue or deep within the cheek pouch. If any portion of the dose is visibly rejected or lost, re-dosing is recommended.

---

Duration of Use

UlcerGard is utilized for administration during periods of high physiological stress, such as competition or travel. The maximum duration of continuous use is 28 days. This duration is intended to cover the entire anticipated stressful period, maintaining acid suppression throughout the risk window.

UlcerGard: Recent Clinical Evidence

---

Evidence for use in Prevention of Gastric Ulcer Development

The research base supporting this medicine's approved use includes Randomized Controlled Trials (RCTs), a study design used to limit bias and explore specific outcomes. These studies typically was evaluated in a comparison between subjects receiving the omeprazole paste and subjects receiving a non-medicated, sham control. The research primarily examined Adult Performance Horses in training or competition regimens. Studies explored outcomes such as the incidence or occurrence of new ulcers and monitored changes in the endoscopic severity score of lesions. The findings describe patterns observed in the studies where controlled trials reported data related to the rate of ulcer development between the omeprazole group and the control subjects. This research provides context regarding patterns of short-term changes observed in a high-risk study population.

---

Study Follow-up Duration and Extended Administration

Clinical research primarily involves studies conducted during periods of increased stress, focusing on short-term symptom changes. Follow-up durations were limited in the key studies supporting this specific use. The continuous administration of the omeprazole paste was observed in trials typically over a defined time interval, commonly 28 days, which corresponded to an acute phase of training. Long-term effects are not fully established, and there is limited information for outcomes of prophylaxis extending beyond the few weeks covered in the initial trials. Data are still emerging for strategies requiring continuous administration over many months.

---

Evidence in Specific and Non-Performance Populations

The results apply only to the populations studied, which were predominantly adult performance horses confirmed to be ulcer-free before trial initiation. Data for certain groups remain insufficient. Specific groups where research is currently limited include foals, weanlings, and pregnant mares. The established research is restricted to specific adult subjects in high-stress settings, and some early confirmatory trials featured small sample sizes.

---

What is Still Uncertain About UlcerGard's Research Base

Key gaps currently exist, and research is ongoing. For instance, some initial trials reported heterogeneity across studies concerning the prophylactic dose examined. The research does not fully characterize the need for continuing prophylactic use once the acute period of high stress has ended. Furthermore, existing studies provide limited insight into the general patterns of ulcer incidence across all breeds or in subjects with complex comorbidities. The overall evidence quality varies across studies primarily due to differences in populations and trial design.

Key Studies & References

1. FREEDOM OF INFORMATION SUMMARY NADA 141-227 ULCERGARD omeprazole: For the prevention of gastric ulcers in horses
2. ULCERGARD® (omeprazole) Oral Paste for Horses Prescribing Information (FDA-Approved Labeling)

Common questions about UlcerGard (FAQ)

Q: Are there any common side effects from UlcerGard I should know about?

A: Official regulatory documents indicate that the safety profile is generally well-characterized. In key clinical and field trials, no adverse reactions attributable to the treatment were observed.

Q: Are there any long-term side effects associated with UlcerGard?

A: The official product safety information establishes clear boundaries for continuous use. Regulatory documents state that the safety of the medicine has not been formally determined for administration periods longer than 91 days.

Q: Why is UlcerGard sometimes recommended for short-term use only?

A: The medicine is approved for administration during anticipated periods of high physiological stress, such as travel or competition. The maximum continuous duration of use for prevention, as approved by regulatory bodies, is 28 days. This duration reflects the time frame studied and is not intended for continuous use extending indefinitely.

Q: Does UlcerGard interact with blood pressure medicine?

A: The official regulatory label does not list specific drug names, including blood pressure medications. However, the medicine's principle of sustained gastric acid suppression can potentially change how other co-administered medicines that require an acidic environment are absorbed by the body.

Q: Is UlcerGard known to interact with commonly used non-prescription pain relievers?

A: The official regulatory label is silent on specific named non-prescription pain relievers. The medicine's core action, which involves reducing stomach acid, establishes the principle that it could affect the absorption of other substances.

Q: What makes UlcerGard different from other stomach treatments I see at the pharmacy?

A: UlcerGard is an FDA-approved, non-prescription veterinary medicine specifically for the equine population. It is formulated as an oral paste containing omeprazole, a Proton Pump Inhibitor (PPI) that provides sustained acid suppression, unlike general antacids which offer only temporary neutralization.

Q: Are there any clinical trials that compared UlcerGard to a placebo?

A: Studies supporting the medicine's approved use include Randomized Controlled Trials (RCTs). In these trials, the omeprazole paste was compared to a non-medicated 'sham control' to examine the rates of ulcer development.

Q: Has UlcerGard been studied in different ethnic groups?

A: UlcerGard is strictly approved as a veterinary medicine for use in the equine (horse) population. The research evidence pertains only to this animal species.

Q: What is the longest period a person is described as using UlcerGard in studies?

A: The product is a veterinary medicine and is strictly prohibited for human use. Regulatory documents state that it is contraindicated for humans.

Q: Is UlcerGard the same as the prescription version?

A: UlcerGard is the non-prescription product approved for the prevention of gastric ulcers. A separate, higher-dose prescription product exists that contains the same active ingredient but is approved specifically for the treatment of existing ulcers.

Q: Why is UlcerGard available over-the-counter?

A: The drug is approved for non-prescription, over-the-counter use because, for the purpose of ulcer prevention in horses, a formal diagnosis of gastric ulcer disease is not required.

Q: How quickly can I expect UlcerGard to start working?

A: The medicine’s action is defined by its ability to irreversibly inhibit the proton pump, which is the final step in acid secretion. This mechanism results in a sustained blockage of acid release, supporting its once-daily administration for sustained effect.

Q: Can taking UlcerGard make me feel tired or drowsy?

A: The official regulatory labeling states that no adverse reactions, including those that would affect the central nervous system like tiredness or drowsiness, were observed in key clinical trials.

Q: Is it normal to feel no difference immediately after taking UlcerGard?

A: UlcerGard is approved for prevention, which is a goal that may not involve immediately noticeable changes in symptoms. Its mechanism of action is for sustained acid suppression, not instant acid neutralization.

Q: Does UlcerGard help with heartburn specifically?

A: The approved indication for UlcerGard is for the prevention of gastric ulcers in the equine species. Heartburn is not an approved indication for this veterinary product.

Q: Can UlcerGard be taken with antacids?

A: The product's regulatory profile does not list specific rules regarding co-administration with antacids. The drug works by sustained acid suppression, a principle that may affect the absorption of other medicines.

Q: What should I do if I experience an unusual reaction to UlcerGard?

A: The label advises users to contact a veterinarian if any questions or concerns arise about the use of the medicine, or if the animal's condition worsens.

Q: What if I take UlcerGard but my symptoms don't go away?

A: The medicine is approved only for the prevention of ulcers. Product information states that a veterinarian should be contacted if the animal's condition is worsening or if symptoms persist.

Q: Is there a generic version of UlcerGard available?

A: The initial FDA approval for UlcerGard included a period of three years of marketing exclusivity. The availability of a generic version is subject to regulatory processes following the expiration of that exclusivity.

Q: How does UlcerGard get processed by the body?

A: The active ingredient, omeprazole, is a substance generally known to be metabolized in the liver. This process is how the body breaks down the drug.

Q: Does UlcerGard have a black box warning described by the FDA?

A: The official regulatory labeling for this veterinary medicine establishes clear safety constraints but does not utilize a Black Box Warning.

Q: Is it possible for UlcerGard to cause an allergic reaction?

A: Official regulatory documents state that the product is contraindicated for animals with a known hypersensitivity or allergy to the active ingredient, omeprazole.

Q: Are there any food or drinks that interfere with UlcerGard?

A: The regulatory label is silent on specific interactions with food, alcohol, or herbal products. However, the administration protocol requires that the medicine be given when the horse’s mouth is free of feed.

Q: Does UlcerGard affect the way other vitamins or supplements work?

A: The drug's mechanism of sustained acid suppression can potentially affect the absorption of other substances, including certain medicines and products that require an acidic environment to be absorbed.

Q: Is UlcerGard generally well-tolerated?

A: The official safety profile is characterized by the absence of observed adverse reactions attributable to the treatment in key clinical and field trials, suggesting the medicine is generally well-tolerated within the approved conditions of use.

Q: Do I need a doctor's diagnosis to use UlcerGard?

A: The product is non-prescription (over-the-counter) and approved for lay use. Regulatory documents confirm that a diagnosis of gastric ulcer disease is not required when the medicine is used for prevention.

Q: Is UlcerGard known to cause stomach upset?

A: The official safety profile, based on controlled studies, indicates that no adverse reactions, including stomach upset, were observed in key clinical and field trials.

Q: Can I drive after taking UlcerGard?

A: UlcerGard is a veterinary medicine and is strictly contraindicated for human use.

Q: Can UlcerGard be used by people with diabetes?

A: UlcerGard is a veterinary medicine approved only for the equine species and is strictly contraindicated for human use.

Q: What are the general expectations for the overall duration of effect after one use of UlcerGard?

A: The drug's mechanism involves the irreversible inhibition of the proton pump, which results in a sustained blockage of acid release. This prolonged effect is what supports the standard once-daily administration.

How to Store and Dispose of UlcerGard

UlcerGard (omeprazole paste) must be stored according to specific regulatory temperature constraints to ensure product stability.

Required Storage Conditions

Storage is mandated at 68 mathrmF to 77 mathrmF (20 mathrmC to 25 mathrmC). The official labeling permits brief temperature excursions between 59 mathrmF to 86 mathrmF (15 mathrmC to 30 mathrmC).

Protection and Disposal

The product must be kept out of the reach of children to prevent accidental human ingestion, as it is strictly a veterinary medicine. For disposal, official instructions prohibit the use of UlcerGard in horses that are intended for human consumption.